Lung Bioengineering’s patient-centric approach is ingrained in our DNA. Just like our parent companies, we are dedicated to addressing the unmet needs of our patients and delivering value to the wider communities in which we are based.
UNITED THERAPEUTICS CORPORATION
United Therapeutics Corporation was founded in 1996 by Martine Rothblatt following the diagnosis of her daughter with pulmonary arterial hypertension (PAH). A biotech company born out of exceptional circumstances, United Therapeutics develops unique products for chronic and life-threatening cardiovascular diseases as well as cancer.UNITHER.COM
LUNG BIOTECHNOLOGY PBC
Under the name of Lung Rx, Lung Biotechnology was established in 2006 as part of United Therapeutics’ work to address the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.LUNGBIOTECHNOLOGY.COM
LUNG BIOENGINEERING INC
Founded in 2014, Lung Bioengineering Inc. is a wholly-owned subsidiary of Lung Biotechnology PBC. Our mission is to be the most trusted provider of centralized organ services, delivering a seamless customer experience and supporting innovative research in order to expand the supply of transplantable organs. As of September 2020, 150 lungs that went through EVLP at Lung Bioengineering have been transplanted as part of our clinical trials.* This number reflects our potential impact in the transplant field.*Not related to the XPS device.
We work on the lungs like a medical team works on a patient.
OUR ORGAN MANUFACTURING PIPELINE
Our next-generation therapies are designed to address the unmet needs of patients living with conditions such as PAH, PH, and end-stage organ disease.VISIT PIPELINE.UNITHER.COM
THE FUTURE OF OUR CENTRALIZED EVLP MODEL
As we work towards the future, we are expanding our capabilities to deliver a true 360-degree service model for organ transplantation.
Our 360 model will encompass hearts, kidneys, livers and lungs in addition to broadening the transplantation services and technologies we offer.
Our services will evolve over time, from assisting in logistics and providing real-time access to data today, to facilitating procurement and supporting therapeutic advancements in the future.
EVLP Specialist candidates must have significant clinical experience in donation/transplantation. All EVLP Specialists undergo intensive EVLP training, both in-house at Lung Bioengineering and at Toronto General Hospital where the technology was pioneered.
YEARS OF OUR CLINICAL TEAM EXPERIENCE IN DONATION, TRANSPLANTATION AND EVLP
QUALITY & COMPLIANCE ASSURANCE
In addition to clinical staff, each facility employs quality assurance and AV/IT staff who participate remotely in each EVLP case.
AV/IT staff complete system checks before the lungs arrive and monitor the AV equipment during the procedure to ensure transplant centers have access to all EVLP data and videos.
Quality Assurance oversight ensures adherence to Standard Operating Procedures as well as verification of key EVLP data, thereby acting as an independent reviewer of data transmitted to the transplant center.
Lung Bioengineering clinical staff are available at all times to triage referrals from transplant centers and carry out EVLP procedures. Our on-call team is no more than one hour away from their respective facility at any given time.
Each of Lung Bioengineering's surgical suites contains specialized A/V equipment and integration that gives transplant centers a clear and detailed view of every aspect of the EVLP procedure.
A/V equipment from both facilities is linked to our XMX system which presents transplant physicians with all EVLP data regardless of which facility receives the lungs.